CVR Medical (OTCMKTS:CRRVF) and Co-Diagnostics (NASDAQ:CODX) Head to Head Analysis

Co-Diagnostics (NASDAQ:CODX) and CVR Medical (OTCMKTS:CRRVF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Co-Diagnostics and CVR Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	0	1	0	0	2.00
CVR Medical	0	0	0	0	0.00

Co-Diagnostics currently has a consensus price target of $1.50, suggesting a potential upside of 111.86%. Given Co-Diagnostics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Co-Diagnostics is more favorable than CVR Medical.

Volatility & Risk

Co-Diagnostics has a beta of -0.63, meaning that its share price is 163% less volatile than the S&P 500. Comparatively, CVR Medical has a beta of 22.67, meaning that its share price is 2,167% more volatile than the S&P 500.

Insider and Institutional Ownership

15.0% of Co-Diagnostics shares are owned by institutional investors. 6.1% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Co-Diagnostics and CVR Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-563.93%	-54.94%	-49.28%
CVR Medical	N/A	N/A	N/A

Earnings & Valuation

This table compares Co-Diagnostics and CVR Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$7.32 million	3.09	-$35.33 million	($1.38)	-0.51
CVR Medical	N/A	N/A	N/A	N/A	N/A

CVR Medical has lower revenue, but higher earnings than Co-Diagnostics.

Summary

Co-Diagnostics beats CVR Medical on 5 of the 9 factors compared between the two stocks.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

About CVR Medical

CVR Medical Corp., a healthcare company, engages in the research and development of subsonic, infrasonic, and low frequency sound wave analysis technology for the healthcare sector. The company provides carotid stenotic scan device, a diagnostic tool to detect and measure carotid arterial stenosis. It offers its products for patients, payors, and healthcare providers. CVR Medical Corp. was incorporated in 1980 and is headquartered in North Vancouver, Canada.